Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Surfaxin lucinactant: Phase II

In an ongoing, open-label, dose-ranging U.S. Phase II trial,

Read the full 95 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE